Advertisement


Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

EHA Hybrid Congress 2023

Advertisement

Paolo Corradini, MD, of Italy’s Istituto Nazionale Dei Tumori, discusses findings from the CART-SIE Real Life Italian Study, which compared treatment outcomes for patients with relapsed or refractory primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL), all of whom received axicabtagene ciloleucel. The trial showed that those with PMBCL had superior survival outcomes than did those with DLBCL.



Related Videos

Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses new data on improved outcomes in patients with relapsed or refractory acute lymphoblastic leukemia who received the combination of mini-HCVD and reduced-dose inotuzumab and then blinatumomab in sequence. In mini-HCVD, cyclophosphamide and dexamethasone are administered with a 50% dose reduction, methotrexate with a 75% dose reduction, cytarabine with an 83% dose reduction, and anthracycline is omitted entirely. (Abstract S119)

Arnon Kater, MD, PhD on CLL: Recent Data on Venetoclax, Ibrutinib, and Undetectable MRD

Arnon Kater, MD, PhD, of the University of Amsterdam Medical Centers, discusses results from the phase II VISION/HO141 trial of venetoclax plus ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). For patients with undetectable measurable residual disease (MRD) after 15 cycles of treatment, treatment cessation with MRD-guided reinitiation was found to be a feasible approach.

Lymphoma
Hematologic Malignancies
Immunotherapy

Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy

Matthew J. Frank, MD, PhD, of Stanford University School of Medicine, discusses new findings showing that CD22 chimeric antigen receptor (CAR) T-cell therapy is an effective and safe salvage therapy for patients with CAR19-refractory large B-cell lymphoma. A multicenter phase II clinical trial is planned for 2023 (Abstract S230).

Leukemia
Hematologic Malignancies

Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase I/II findings from the Bruin study of resistance to pirtobrutinib in patients with covalent BTK inhibitor–pretreated chronic lymphocytic leukemia (CLL). The aim of the study was to explore the genomic evolution of resistance to this agent.

Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Rami S. Komrokji, MD, of Moffitt Cancer Center, discusses an assessment of new classifications for myeloid neoplasms and the ongoing efforts to harmonize these classifications, so researchers can better understand risk, outcomes, and survival among patients with genetically distinct types of the disease.

Advertisement

Advertisement




Advertisement